Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma issues new shares to Ergomed plc

(Stockholm, 20 February, 2020) Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 21 January 2020, issue 301,724 new shares to Ergomed plc (“Ergomed”), the CRO carrying out Asarina Pharma’s phase IIb PMDD study.

Full PDF

Asarina Pharma’s extraordinary general meeting

Today, on 21 January 2020, Asarina Pharma AB (publ) held an extraordinary general meeting (“EGM”) in Stockholm, Sweden. The EGM elected the chairman of the board of directors Paul de Potocki as chairman of the meeting and advokat Nina Johnsson with Fredersen Advokatbyrå to take minutes at the meeting. The EGM resolved upon, inter alia,…

Full PDF


The shareholders of Asarina Pharma AB (publ) are hereby summoned to attend the Extraordinary General Meeting (“EGM”) on 21 January 2020, at 10.00 at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CET and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice, which…

Full PDF

First patient dosed in landmark Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.

Full PDF

Asarina Pharma AB (publ) Interim Report Q3 2019 released

Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study, received FDA approval for our IND in menstrual migraine and included the first patient in our menstrual migraine study. After the end of the quarter a new directed share issue…

Full PDF